Abstract:At present, pulmonary fibrosis (PF) is a prevalent and irreversible lung disease with limited treatment options, and idiopathic pulmonary fibrosis (IPF) is one of its most common forms. Recent research has highlighted PF as a metabolic-related disease, including dysregulated iron, mitochondria, lipid, and glucose homeostasis. Systematic reports on the regulatory roles of glucose metabolism in PF are rare. This study explores the intricate relationships and signaling pathways between glucose metabolic processes and PF, delving into how key factors involved in glucose metabolism regulate PF progression, and the interplay between them. Specifically, we examined various enzymes, such as hexokinase (HK), 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3), pyruvate kinase (PK), and lactate dehydrogenase (LDH), illustrating their regulatory roles in PF. It highlights the significance of lactate, alongside the role of pyruvate dehydrogenase kinase (PDK) and glucose transporters (GLUTs) in modulating pulmonary fibrosis and glucose metabolism. Additionally, critical regulatory factors such as transforming growth factor-beta (TGF-β), interleukin-1 beta (IL-1β), and hypoxia-inducible factor 1 subunit alpha (HIF-1α) were discussed, demonstrating their impact on both PF and glucose metabolic pathways. It underscores the pivotal role of AMP-activated protein kinase (AMPK) in this interplay, drawing connections between diabetes mellitus, insulin, insulin-like growth factors, and peroxisome proliferator-activated receptor gamma (PPARγ) with PF. This study emphasizes the role of key enzymes, regulators, and glucose transporters in fibrogenesis, suggesting the potential of targeting glucose metabolism for the clinical diagnosis and treatment of PF, and proposing new promising avenues for future research and therapeutic development.

Glycolytic reprogramming in organ fibrosis: New dynamics of the epigenetic landscape

Metabolic reprogramming of pulmonary fibrosis

Epigenetic modifications in fibrotic diseases: implications for pathogenesis and pharmacological targets.

Epigenetic Modifications in Fibrotic Diseases: Implications for Pathogenesis and Pharmacological Targets

Targeting tumor suppressor p53 for organ fibrosis therapy

Epithelial-mesenchymal Transition in Organ Fibrosis Development: Current Understanding and Treatment Strategies

A New Hypothetical Concept in Metabolic Understanding of Cardiac Fibrosis: Glycolysis Combined with TGF-β and KLF5 Signaling

Epigenetic Regulation of Fibroblasts and Crosstalk between Cardiomyocytes and Non-Myocyte Cells in Cardiac Fibrosis

m6A epitranscriptomic and epigenetic crosstalk in cardiac fibrosis

Deciphering the cellular mechanisms underlying fibrosis-associated diseases and therapeutic avenues

Epigenetic signatures in cardiac fibrosis: Focusing on noncoding RNA regulators as the gatekeepers of cardiac fibroblast identity

New aspects of the epigenetic regulation of EMT related to pulmonary fibrosis

The Landscape of Histone Modification in Organ Fibrosis

Advances in the understanding of the role and mechanism of action of PFKFB3‑mediated glycolysis in liver fibrosis (Review)

Glycolysis and beyond in glucose metabolism: exploring pulmonary fibrosis at the metabolic crossroads

Thermodynamic Aspects and Reprogramming Cellular Energy Metabolism during the Fibrosis Process

Transforming growth factor-β signaling: From tissue fibrosis to therapeutic opportunities

Mitochondrial quality control in liver fibrosis: Epigenetic hallmarks and therapeutic strategies

The role of metabolic reprogramming and de novo amino acid synthesis in collagen protein production by myofibroblasts: implications for organ fibrosis and cancer

A New Target for Hepatic Fibrosis Prevention and Treatment: The Warburg Effect

Inhibiting Aerobic Glycolysis Suppresses Renal Interstitial Fibroblast Activation and Renal Fibrosis.